Skip to main content
Premium Trial:

Request an Annual Quote

Evotec Inks Screening Pact with Active Biotech

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Evotec said today that it will use its high-throughput compound screening and assay development technologies to identify small molecule modulators for a target selected by Stockholm-based Active Biotech.

Under the agreement, Evotec will use its high-throughput and surface plasmon resonance screens with its Lead Discovery Library to identify and validate novel hits that will complement ongoing Active Biotech studies of a target that may be involved immune disorders and cancer.

Evotec has developed assays and high-throughput screens for a range of target classes, including GPCRs, kinases and other enzymes, and ion channel and protein interactions.

Financial terms of the agreement were not released.